In this perspective, several strategies are under investigation to efficiently deliver these molecules against BC-related ncRNA targets, such as synthetic ionizable lipids (LNP), including ASOs targeting MALAT1 and HOTAIR lncRNAs (201) or ZIF-90 (202) nanoparticles enveloping dual antisense oligonucleotide targeting miR-21/miR-155 to treat TNBC and inhibit metastasis. This evidence concerns the gene MALAT1 and breast cancer.